CHMP plays a crucial role in the approval process of cancer drugs within the European Union. When a pharmaceutical company develops a new cancer treatment, it must submit comprehensive clinical trial data to CHMP for review. The committee then rigorously evaluates the safety, efficacy, and quality of the drug before granting marketing authorization.
